2016年3月FDA批准了Elusys Therapeutics公司一种新的吸入性炭疽治疗药物obiltoxaximab(Anthim)。该药是一种单克隆抗体,与炭疽杆菌(anthrax)产生的毒素结合,抑制毒素与细胞受体的结合,阻止细胞内炭疽致死因子和水肿因子、炭疽毒素的致病作用。其作用机制尚不清楚。与适当的抗菌药联用,可用于成人 March 2016 The FDA approved Elusys Therapeutics, a new obstructive anthrax drug obiltoxaximab (Anthim). This drug is a monoclonal antibody that binds toxins produced by anthrax and inhibits the binding of toxins to cellular receptors and prevents the pathogenic effects of anthrax lethal and edematous factors and anthrax toxin in cells. Its mechanism of action is not clear. In combination with appropriate antibacterials, it can be used in adults